pdufa.bio
Home › Decisions › MRK 2026-06-24

MRK FDA decision — Jun 24, 2026

✓ APPROVED

Merck & Company Inc. — Trodelvy (sacituzumab govitecan-hziy) plus K · Inoperable (unresectable) locally advanced or meta.

Run-up into the decision (T-120 → T+5)

PDUFA 6/24/26$123.93$105.261/7/26
Daily close, T-120 (1/7/26) through T+5. Run-up high $123.93 on 2/27/26, low $105.26 on 1/8/26 (T-120 to T-1). FDA decision 6/24/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-24
OutcomeApproved
Drug / candidateTrodelvy (sacituzumab govitecan-hziy) plus K
CompanyMerck & Company Inc.
120-day run-up (T-120→T-1)+12.8%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio